Comparator: etoricoxib — Competitive Intelligence Brief

Comparator: etoricoxib (Comparator: etoricoxib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective COX-2 inhibitor (coxib). Area: Rheumatology / Pain Management.

phase 3 Selective COX-2 inhibitor (coxib) COX-2 (Cyclooxygenase-2) Rheumatology / Pain Management Small molecule

Target snapshot

Comparator: etoricoxib (Comparator: etoricoxib) — Organon and Co. Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce prostaglandin production and inflammation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Comparator: etoricoxib TARGET	Comparator: etoricoxib	Organon and Co	phase 3	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
Celecoxib (Celebrex)	Celecoxib (Celebrex)	National Eye Institute (NEI)	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
Celecoxib 200 milligrams	Celecoxib 200 milligrams	Pfizer	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
parecoxib, valdecoxib, parecoxib and dexamethasone	parecoxib, valdecoxib, parecoxib and dexamethasone	Asker & Baerum Hospital	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
Parecoxib and Celecoxib	Parecoxib and Celecoxib	Peking Union Medical College Hospital	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (cyclooxygenase-2)
Parecoxib Sodium/Valdecoxib	Parecoxib Sodium/Valdecoxib	Pfizer	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)
Celecoxib 400 milligrams	Celecoxib 400 milligrams	Pfizer	marketed	Selective COX-2 inhibitor (coxib)	COX-2 (Cyclooxygenase-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective COX-2 inhibitor (coxib) class)

1. Pfizer · 4 drugs in this class
2. Organon and Co · 2 drugs in this class
3. Laboratorios Silanes S.A. de C.V. · 2 drugs in this class
4. University of Malaya · 2 drugs in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. National Eye Institute (NEI) · 1 drug in this class
7. Novartis · 1 drug in this class
8. Peking Union Medical College Hospital · 1 drug in this class
9. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
10. Radboud University Medical Center · 1 drug in this class